Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

Sponsor
Fudan University
Study ID
NCT07120451
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced Ovarian Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Senaparib — DRUG
    100mg qd
  • Bevacizumab — DRUG
    7.5mg/kg q3w

Study Details

This study is a Prospective, Single-arm, Phase II clinical trial. The purpose of this study is to find out if taking combination therapy of Senaparib and Bevacizumab is safe and works well for people with first-line maintenance therapy in newly diagnosed advanced homologous recombination proficient ovarian cancer, and explore relevant biomarkers for evaluating the efficacy of maintenance therapy through exosome. Researchers will look at the Progression-Free Survival, Overall Survival, safety, and any side effects.

Key Dates

First listed
Aug 13, 2025
Start date
Oct 10, 2025
Status verified
Aug 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2028

Study Design

Enrollment
37 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Senaparib+Bevacizumab
    Participants will receive Senaparib and Bevacizumab in combination. Senaparib qd for 2 years and Bevacizumab q3w for 15 months.

Primary Outcome Measure

PFS [ Time Frame: approximately 2 years ]

Central Contacts

Related Studies